Generic penetration in the retail atypical antipsychotic market

Susan Lenderts, Amir H. Kalali, Peter F Buckley

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


In this article, we explore the penetration of generic atypical antipsychotics in the United States market before and after the availability of generic risperidone in July 2008. Analysis suggests that, overall, generic penetration into the atypical antipsychotic market has grown from approximately three percent in January 2008 to more than 25 percent in December 2009. Similar trends are uncovered when branded and generic prescriptions are analyzed by specialty.

Original languageEnglish (US)
Pages (from-to)9-10
Number of pages2
JournalPsychiatry (Edgemont)
Issue number3
StatePublished - Mar 1 2010


  • Atypical antipsychotic
  • Brand
  • Generic
  • Generic penetration
  • Prescription
  • Psychiatrists
  • Risperidone
  • Trade

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Generic penetration in the retail atypical antipsychotic market'. Together they form a unique fingerprint.

Cite this